A double-blind, placebo-controlled, dose–response study of the effectiveness and safety of lisinopril for children with hypertension

Soffer, Beth A.; Zhang, Zhongxin; Miller, Kenneth M.; Vogt, Beth A.; Shahinfar, Shahnaz

doi:10.1016/s0895-7061(03)00900-2

Cited by 131 publications

(108 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No long-term randomised trials have investigated the effect of kidney function and cardiovascular disease in children or adolescents with diabetes, and the consensus statements are based on extrapolations from adult studies. In short-term studies, ACE inhibitors have been effective and safe in non-diabetic hypertensive children [58,59], but long-term studies are lacking.…”

Section: Atherosclerosis Is Earlier and More Severe In Type 1 Diabetesmentioning

confidence: 99%

Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment?

2005

View full text Add to dashboard Cite

Autopsy studies have shown that atherosclerosis begins in adolescence in otherwise healthy individuals, and imaging techniques have shown that atherosclerosis develops earlier and is more prevalent in children with diabetes than in age-matched healthy controls. Cardiovascular disease has now overtaken diabetic nephropathy as the leading cause of premature mortality in young adults with diabetes, and the emphasis on disease prevention has accordingly shifted to a younger age group. The majority of children and adolescents with diabetes have suboptimal blood glucose control, and this contributes to accelerated arterial disease in this age group. Other conventional risk factors for coronary heart disease also need to be considered and treated aggressively. Effective early prevention of cardiovascular disease will involve lifestyle modification and full implementation of existing treatment guidelines, and largescale prospective studies will be needed to establish the risks and benefits of early pharmacological intervention in children and adolescents.

show abstract

Section: Atherosclerosis Is Earlier and More Severe In Type 1 Diabetesmentioning

confidence: 99%

Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment?

2005

View full text Add to dashboard Cite

show abstract

“…Adolescenti, osobito oni s lošom kontrolom ŠB-a mogu imati brzu progresiju retinopatije 55 . Najsenzitivnije metode za detekciju retinopatije su stereoskopsko fotografiranje očnog dna i fluorescinska angiografija 56 . Retinopatija započinje mikroaneurizmama, hemoragijom i eksudatima.…”

Section: Kronične Komplikacije šB-a Tipaunclassified

“…U pacijenata s perzistentnom mikroalbuminurijom preporučuje se terapija inhibitorima angiotenzin konvertirajućeg enzima (engl. angiotensin converting enzyme; ACE) s ciljem zaustavljanja progresije daljnjeg bubrežnog oštećenja 56 . U djece i adolescenata oboljelih od ŠB-a tipa 1 neuropatija se rijetko vidi.…”

Section: Kronične Komplikacije šB-a Tipaunclassified

Type 1 diabetes mellitus in children

2016

View full text Add to dashboard Cite

Sažetak. Šećerna bolest tipa 1 (ŠB) najčešća je endokrinološka bolest dječje dobi. Karakterizirana je deficitom inzulina koji nastaje zbog autoimunog uništenja β stanica gušterače. Javlja se u genetski predisponiranih osoba, a može biti potaknuta provocirajućim čimbenicima iz okoliša. Incidencija ŠB-a tipa 1 u djece je u porastu, u prvom redu u djece mlađe od 5 godina. Znakovi i simptomi bolesti razvijaju se brzo, obično u periodu kroz nekoliko tjedana. Tipični simptomi su poliurija, polidipsija, polifagija i gubitak na tjelesnoj težini. U nekih pacijenata inicijalni simptom početka ŠB-a tipa 1 je dijabetička ketoacidoza, po život opasno metaboličko stanje. Liječenje ŠB-a tipa 1 tijekom djetinjstva i adolescencije je kompleksno je i zahtjevno. Osnova liječenja pacijenata sa ŠB-om tipa 1 je inzulin. Postoji više različitih pripravaka inzulina i načina aplikacije inzulina. Intenzivirana terapija inzulinom u usporedbi s konvencionalnom terapijom poboljšava kontrolu glikemije i smanjuje dugoročne komplikacije ŠB-a. Važna komponenta u liječenju djece sa ŠB-om tipa 1 je pravilna prehrana. Glavni terapijski cilj je dobra kontrola glikemije (glikolizirani hemoglobin < 7,5 %) kako bi se spriječile kratkoročne i dugoročne komplikacije bolesti. Najčešće komplikacije bolesti u djece su hipoglikemija, hiperglikemija i dijabetička ketoacidoza.Ključne riječi: djeca; inzulin; liječenje; šećerna bolest tipa 1 Abstract. Type 1 diabetes mellitus is the most common chronic endocrine disease worldwide in children. It is characterised by autoimmune destruction of the β cells leading to insulin deficiency. This process occurs in genetically susceptible persons, and is probably triggered by one or more environmental factors. The incidence of type 1 diabetes mellitus is rising, especially in young children (age < 5 years). The signs and symptoms of disease in children usually develop quickly, over a period of a few weeks. Typical symptoms include polyuria, polydipsia and weight loss. In some patients diabetic ketoacidosis, a life-threatening metabolic state, can be the initial presentation of type 1 diabetes mellitus. Diabetes management is complex and challenging, particularly during childhood and adolescence. Insulin therapy is the mainstay in management of type 1 diabetes mellitus. There are many different insulin preparations and delivery systems available. Intensive insulin therapy compared with conventional therapy improves glycemic control and decreases long-term complications of diabetes. Another important issue in the management of children with type 1 diabetes mellitus includes nutrition. The main therapeuthic goal is good glycemic control of the disease (glycated haemoglobin <7,5 %) in order to prevent short and long term diabetic complications. The most common complications of type 1 diabetes mellitus in children include hypoglycemia, hyperglycemia and diabetic ketoacidosis.

show abstract

“…However, its three times daily dosing is inconvenient for patients and families, so oncedaily agents such as lisinopril and enalapril are often used instead, though they have been studied less than captopril in children. Lisinopril has been studied in a double-blind placebo-controlled pediatric study and generally costs less than newer ACE inhibitors [41]. Enalapril has also been studied in children and is currently the only commerciallyavailable solution, though at this time the commercial solution may be more costly than compounded lisinopril, for example.…”

Section: Relevant Within Class Differencesmentioning

confidence: 99%

Pharmacologic Management of Pediatric Hypertension

2015

View full text Add to dashboard Cite

A double-blind, placebo-controlled, dose–response study of the effectiveness and safety of lisinopril for children with hypertension

Abstract: Lisinopril, once daily, is an effective and well-tolerated antihypertensive in children aged 6 to 16 years. An initial dose of 0.07 mg/kg, administered once daily, effectively lowered BP within 2 weeks. Blood pressure was reduced in a dose-dependent fashion.

Cited by 131 publications

References 7 publications

Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment?

Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment?

Type 1 diabetes mellitus in children

Pharmacologic Management of Pediatric Hypertension

Contact Info

Product

Resources

About